H.C. Wainwright lowered the firm’s price target on MannKind (MNKD) to $8 from $11 and keeps a Buy rating on the shares. The stock is down 45% since the announcement about the future of Tyvaso DPI and the respective royalties to MannKind, the analyst tells investors in a research note. The firm sees a “very favorable” risk/reward for the shares based on its view of Furoscix following the pullback.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind downgraded to Sector Perform from Outperform at RBC Capital
- MannKind reports Q4 EPS (5c) vs 3c last year
- RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind
- Leerink sees MannKind selloff as ‘overreaction’ to headline news
- H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition